Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma

A. Sasaki, Y. Iwashita, K. Shibata, M. Ohta, S. Kitano, Masaki Mori

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Aims: To study the effect of preoperative transcatheter arterial chemoembolization (TACE) on long-term survival after hepatic resection for hepatocellular carcinoma (HCC), we conducted a comparative analysis in 235 HCC patients who underwent hepatic resection with a curative intent. Methods: We compared clinicopathologic background, mortality, and survival rates after hepatic resection between those who underwent preoperative TACE (n = 109) and those who did not (n = 126). Results: One hundred and two patients in the TACE group (93.6%) received TACE only once. The mean interval between TACE and hepatic resection was 33.1 days. Patients in the TACE group were younger than those in the non-TACE group, and liver cirrhosis and non-anatomical hepatic resection were more prevalent in this group. The 5-year overall survival rate after hepatic resection was significantly lower in the TACE group (28.6%) than in the non-TACE group (50.6%), especially in patients without cirrhosis or with stage I or II tumor. There was no difference between the two groups in mortality or disease-free survival after hepatic resection. Multivariate analysis showed preoperative TACE, preoperative aspartate aminotransferase elevation, and microscopic portal invasion to be independent risk factors for a poor outcome after hepatic resection. Conclusions: Preoperative TACE should be avoided for patients with resectable HCC, especially for those without cirrhosis or with an early stage tumor.

Original languageEnglish
Pages (from-to)773-779
Number of pages7
JournalEuropean Journal of Surgical Oncology
Volume32
Issue number7
DOIs
Publication statusPublished - Sep 1 2006

Fingerprint

Hepatocellular Carcinoma
Survival Rate
Liver
Fibrosis
Mortality
Aspartate Aminotransferases
Liver Cirrhosis
Disease-Free Survival
Neoplasms
Multivariate Analysis
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Surgery

Cite this

Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. / Sasaki, A.; Iwashita, Y.; Shibata, K.; Ohta, M.; Kitano, S.; Mori, Masaki.

In: European Journal of Surgical Oncology, Vol. 32, No. 7, 01.09.2006, p. 773-779.

Research output: Contribution to journalArticle

@article{0cd053501c694a6cb972de1ecfe2eb7c,
title = "Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma",
abstract = "Aims: To study the effect of preoperative transcatheter arterial chemoembolization (TACE) on long-term survival after hepatic resection for hepatocellular carcinoma (HCC), we conducted a comparative analysis in 235 HCC patients who underwent hepatic resection with a curative intent. Methods: We compared clinicopathologic background, mortality, and survival rates after hepatic resection between those who underwent preoperative TACE (n = 109) and those who did not (n = 126). Results: One hundred and two patients in the TACE group (93.6{\%}) received TACE only once. The mean interval between TACE and hepatic resection was 33.1 days. Patients in the TACE group were younger than those in the non-TACE group, and liver cirrhosis and non-anatomical hepatic resection were more prevalent in this group. The 5-year overall survival rate after hepatic resection was significantly lower in the TACE group (28.6{\%}) than in the non-TACE group (50.6{\%}), especially in patients without cirrhosis or with stage I or II tumor. There was no difference between the two groups in mortality or disease-free survival after hepatic resection. Multivariate analysis showed preoperative TACE, preoperative aspartate aminotransferase elevation, and microscopic portal invasion to be independent risk factors for a poor outcome after hepatic resection. Conclusions: Preoperative TACE should be avoided for patients with resectable HCC, especially for those without cirrhosis or with an early stage tumor.",
author = "A. Sasaki and Y. Iwashita and K. Shibata and M. Ohta and S. Kitano and Masaki Mori",
year = "2006",
month = "9",
day = "1",
doi = "10.1016/j.ejso.2006.04.002",
language = "English",
volume = "32",
pages = "773--779",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma

AU - Sasaki, A.

AU - Iwashita, Y.

AU - Shibata, K.

AU - Ohta, M.

AU - Kitano, S.

AU - Mori, Masaki

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Aims: To study the effect of preoperative transcatheter arterial chemoembolization (TACE) on long-term survival after hepatic resection for hepatocellular carcinoma (HCC), we conducted a comparative analysis in 235 HCC patients who underwent hepatic resection with a curative intent. Methods: We compared clinicopathologic background, mortality, and survival rates after hepatic resection between those who underwent preoperative TACE (n = 109) and those who did not (n = 126). Results: One hundred and two patients in the TACE group (93.6%) received TACE only once. The mean interval between TACE and hepatic resection was 33.1 days. Patients in the TACE group were younger than those in the non-TACE group, and liver cirrhosis and non-anatomical hepatic resection were more prevalent in this group. The 5-year overall survival rate after hepatic resection was significantly lower in the TACE group (28.6%) than in the non-TACE group (50.6%), especially in patients without cirrhosis or with stage I or II tumor. There was no difference between the two groups in mortality or disease-free survival after hepatic resection. Multivariate analysis showed preoperative TACE, preoperative aspartate aminotransferase elevation, and microscopic portal invasion to be independent risk factors for a poor outcome after hepatic resection. Conclusions: Preoperative TACE should be avoided for patients with resectable HCC, especially for those without cirrhosis or with an early stage tumor.

AB - Aims: To study the effect of preoperative transcatheter arterial chemoembolization (TACE) on long-term survival after hepatic resection for hepatocellular carcinoma (HCC), we conducted a comparative analysis in 235 HCC patients who underwent hepatic resection with a curative intent. Methods: We compared clinicopathologic background, mortality, and survival rates after hepatic resection between those who underwent preoperative TACE (n = 109) and those who did not (n = 126). Results: One hundred and two patients in the TACE group (93.6%) received TACE only once. The mean interval between TACE and hepatic resection was 33.1 days. Patients in the TACE group were younger than those in the non-TACE group, and liver cirrhosis and non-anatomical hepatic resection were more prevalent in this group. The 5-year overall survival rate after hepatic resection was significantly lower in the TACE group (28.6%) than in the non-TACE group (50.6%), especially in patients without cirrhosis or with stage I or II tumor. There was no difference between the two groups in mortality or disease-free survival after hepatic resection. Multivariate analysis showed preoperative TACE, preoperative aspartate aminotransferase elevation, and microscopic portal invasion to be independent risk factors for a poor outcome after hepatic resection. Conclusions: Preoperative TACE should be avoided for patients with resectable HCC, especially for those without cirrhosis or with an early stage tumor.

UR - http://www.scopus.com/inward/record.url?scp=33747763295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747763295&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2006.04.002

DO - 10.1016/j.ejso.2006.04.002

M3 - Article

C2 - 16797156

AN - SCOPUS:33747763295

VL - 32

SP - 773

EP - 779

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 7

ER -